Developing early disease detection and comprehensive diagnostic solutions, Baebies is structured around development of products to improve infant healthcare with the firm's primary effort organized around technology under license from Illumina, the global genetic sequencing and genotyping company - also an SBIR involved firm. Illumina had acquired the screening technology in 2013 for $96 million from Advanced Liquid Logic - itself being an SBIR Awardee - and a spin-out of Duke University spinout. In effect, the Baebies principals are continuing to develop the medical technology they had developed while they were at Advanced Liquid Logic . Specializing in Digital Microfluidic Technologies and Platforms. Baebies' primary product is a nimble bioassay automation platform designed to rapidly perform multiplex enzymatic assays and other tests. Other products include SEEKER, a FDA cleared and CE marked newborn screening platform for lysosomal storage disorders, and FINDERTM, a near patient pediatric testing platform that is still under development and not available at this time for sale or use in any territory.
